What this is
- How it works
- How it works isn't classified yet
- Tested for
- Longevity, GLP-1, Geroscience, Aging
- Main trialPhase 2/3
- “The goal of this randomized, controlled trial is to evaluate the effectiveness of alternative therapies (metformin alone, with rapamycin, and with low-dose naltrexone) in maintaining weight loss in patients weaning off GLP-1 medications. The main questions it aims to answer are: * Whether the combination of metformin, with or without rapamycin or low-dose naltrexone, will be adequate to maintain the relative weight of individuals gradually discontinuing GLP-1 receptor agonist use. * Whether individuals discontinuing GLP-1 receptor agonist use who instead use a combination of metformin, with…”In the company’s words, NCT07092618 on ClinicalTrials.gov
- Other names
- sirolimus · Rapamune · Rapacan · Siromus
Other drugs for Aging
- PLH-2301Pluto Inc. · Phase 2
- TJ0113Hangzhou PhecdaMed Co., Ltd. · Phase 2
- MF-300Epirium Bio Inc. · Phase 2
- Bone marrow mesenchymal stem cellsGuangZhou Cellgenes Biotechnology Co., Ltd. · Phase 1/2
- BimagrumabEli Lilly · Phase 2
- EN001ENCell · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials23
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | Aug 2025 | Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation | |
| Phase 3Completed | 9 Apr 2026 | Combination Gerotherapeutic Interventions for Healthspan Improvement | |
| Phase 2Completed | 30 Dec 2023 | Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study | |
| Phase 2Authorised | not given | Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment in children with tuberous sclerosis complex (TSC) under 4 months of age (PROTECT) | |
| Phase 4Expired | not given | Evaluation and promotion of specific adaptative immunity against polyomavirus (BKV) to prevent viral infection after kidney transplantation (BK-VAX project) | |
| Phase 2Not authorised | not given | A geroscience approach to post-acute COVID-19 syndrome (PACS) by Diet and Exercise plus rapamycin or metformin to treat Frailty and restore immune functions: a randomized, single center clinical trial. | |
| Phase 3Authorised | not given | Prospective comparison of sirolimus against corticosteroids in treatment of patients with active thyroid eye disease | |
| Phase 2Authorised | not given | A single arm single center exploratory observational phase II study, aimed to detect long term changes in volume of port-wine macrocheilia and color of port-wine stain in patients undergoing surgery and laser therapy during sirolimus treatment. Quality of life and efficacy and safety of sirolimus will be assessed. | |
| Phase 2Authorised | not given | Safety study for the use of Rapamycin in children with familial adenomatous polyposis - RAPA-4-FAP | |
| Phase 2/3Authorised | not given | Randomized, placebo-controlled, double-blind and double-dummy clinical trial comparing the safety, tolerability, and efficacy of vigabatrin and rapamycin in a preventive treatment of infants with Tuberous Sclerosis Complex | |
| Phase 2Authorised | not given | SIRIUS Sarcoidosis with moderate to severe facial skin involvement: an open multicenter study of the efficacy and safety of oral sirolimus | |
| Phase 3Authorised | not given | Multicenter, randomized, double-blind, placebo controlled study to assess the efficacy and safety of RApamycin in drug Resistant Epilepsy associated with TSC | |
| Phase 2Ended | not given | Open, randomized, IInd phase clinical study evaluating the safety and efficacy of rapamycin in the treatment of drug-resistant epilepsy in children with rare and ultra rare diseases of the central nervous system associated with the activation of the mTOR pathway : BraimTOR-NEURO | |
| Phase 2Ended | not given | An open randomized phase II clinical trial evaluating the safety and efficacy of rapamycin in the treatment of gliomas high-grade malignant gliomas in children as part of the establishment management of rare and ultra rare diseases of the central nervous system associated with mTOR pathway activation: BraimTOR- ONKO | |
| Phase 2Authorised | not given | Multicenter, open label study using molecularly determined targeted therapies in children 3-18 years of age with DIPG (diffuse intrinsic pontine glioma- DIPG)- DIPGen | |
| Phase 2Ended | not given | TOPical sirolimus in linGUal microkystic lymphatic malformation | |
| Phase 2Authorised | not given | MAV-RAPA: Prospective evaluation of the efficacy of sirolimus (Rapamune) in the treatment of superficial arteriovenous malformations. | |
| Phase 4Authorised | not given | Safety and efficacy of steering of immunosuppression based on BKPyV-specific T cells in case of BK Polyomavirus (BKPyV) DNAe- mia after kidney transplantation | |
| Phase 4Authorised | not given | SIROLIMUS VERSUS MYCOPHENOLATE MOFETIL IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE RISK OF HERNIA | |
| Phase 2Authorised | not given | RAPAMALYMPH - Evaluation of the Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations of Poor Prognosis | |
| Phase 4Authorised | not given | Use of tacrolimus and MTOR inhibitors with anticipatory therapy vs. tacrolimus and mycophenolic acid with universal prophylaxis in renal recipients at high risk of post-transplant cytomegalovirus. Phase IV clinical trial (TIMTOR STUDY). | |
| Phase 2Authorised | not given | Immunotherapy with a JAK1/JAK2 inhibitor (baricitinib) and an mTORC1 inhibitor (sirolimus), alone and in combination, for the control of HIV-1 replication after antiretroviral treatment interruption: a phase II multicenter, multi-arm, multi-stage, randomized, double-blind, placebo-controlled, adaptative trial | |
| Phase 1/2Authorised | not given | Phase I/II trial of Dinutuximab beta in combination with Irinotecan and Rapamycin in pediatric, adolescents and adult patients with relapsed/refractory bone tumors. BONE DINIRRA |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026